Csl Stock Earnings Reports

CSL reported FY25 revenue growth of 5% (constant currency) with NPATA up 14% and NPAT up 17%. All three business units grew: CSL Behring (+6%), CSL Seqirus (+2%), and CSL Vifor (+8%). Free cash flow rose 58%, net debt/EBITDA improved to 1.8x, and the final dividend was increased by 12% to USD 1.62 per share. Management announced a major transformation program to simplify the operating model, target higher R&D and commercial productivity, and reduce costs, with a target of over USD 0.5 billion of annual pretax savings by end-FY28 and one-off restructuring charges (to be recognized in FY26). CSL also announced intent to demerge CSL Seqirus into a separate ASX-listed company in FY26 and reintroduced a multiyear on-market share buyback program (starting with ~AUD 750m in FY26). FY26 group revenue growth is guided to ~4–5% (constant currency). NPATA for FY26 (excluding nonrecurring restructuring costs) is guided to approximately USD 3.45–3.55 billion (7–10% growth vs FY25). Management expects the majority of transformation savings to be realized in FY27–FY28, with about 50% of savings targeted for reinvestment into high-priority clinical and commercial opportunities. Key near-term headwinds called out include IRA Part D impacts, softer seasonal influenza demand versus pandemic levels, product launch timing (e.g., ANDEMBRY, HEMGENIX), FX headwinds, and increased competition/tendering in some markets. Capital allocation priorities include continued investment in growth (including potential Ig capacity expansion in the U.S.), dividends, and the new buyback program.